WELCOME TO THE
JANDA LAB
News from the lab
Our group merges chemical and biological approaches into a cohesive research program. We explore the intersection of chemistry and immunology, with a particular focus on harnessing the power of adaptive immune responses and functional antibody design. Our diverse research interests entail catalytic antibody development, biochemical reactivity of drugs of abuse and immunopharmacotherapy for drug abuse, regulation of body weight and metabolism, detection of and protection from warfare agents, bacterial cell-cell communication, phage display technology, neglected tropical disease diagnostics and therapeutics as well as organic synthesis methods.
The information on the Janda Lab website represents that of the author and not that of Scripps Research. The Janda Lab takes full responsibility for the information presented. Accidental errors will be corrected in a timely manner.
A molecule discovered in the lab more than a decade ago has just been approved as a new drug for brain cancer!
An article covering this story was just published in the Union Tribune.
NEW PUBLICATION:
"Fentanyl-Rewired: A 2-Azaspiro[3.3]heptane Core Preserves μ-Opioid Function"
Award for Dr. Janda at the
19th Annual Botulinum Research Center Symposium
DHS reports on our paper in their Chemical Security Analysis Center Chemical Current News Report (02/20/2026). (Download PDF)